Safety Study of Multikine in the Treatment of Perianal Warts

NCT ID: NCT02115919

Last Updated: 2016-08-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-04-30
• Study Completion Date: 2016-01-31

Brief Summary

Caused by the human papillomavirus (HPV), anogenital warts are a common sexually-transmitted infection (STI). They are distressing to those who have them and are a source of viral shedding and transmission to others. Treatment of warts is aimed at destruction of the lesion.

Objectives:

1. Establish safety of Multikine in treatment of perianal condyloma.

2. Describe presence of anal HPV and anal dysplasia in participants with perianal condyloma.

3. Describe adverse effects associated with Multikine in the management of perianal condyloma.

Design:

Phase I, dose-escalation trial. Potential participants desiring treatment for their perianal warts will be referred to study by their primary clinician. All participants will undergo baseline anal Pap, anal HPV subtyping, perianal condyloma characterization (count, measurement, photography), and complete a baseline questionnaire. Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days. If no serious adverse events are noted after 4 weeks of therapy, cohort B will be studied using the same schedule but with a dose of 400IU per treatment. Each participant will undergo anal Pap and anal HPV subtyping once weekly during treatment. Condyloma characterization (count, measurement, photography) will occur prior to each treatment. After treatment completed, participants will complete a follow-up visit at 70, 100, 130, 160 days and have anal Pap, anal HPV subtyping, and perianal condyloma characterization (count, measurement, photography) performed.

Subjects:

The study will be open to adult men and women who are HIV-infected who receive medical care from the Naval Medical Center San Diego.

Main Outcome Measures:

1. Perianal wart characterization [count, measurement (in millimeters diameter)], photography)

2. HPV subtype in anal canal

3. Anal dysplasia cytologic grade

4. Questionnaire responses

5. Adverse effects experienced during treatment, recorded in symptom log

Detailed Description

There are no further details to describe regarding this research project

Conditions

Condyloma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort A

Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.

Group Type: EXPERIMENTAL

Leukocyte Interleukin, Injection 200IU

Intervention Type: DRUG

Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.

Cohort B

Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.

Group Type: EXPERIMENTAL

Leukocyte Interleukin, injection 400IU

Intervention Type: DRUG

Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.

Interventions

Leukocyte Interleukin, Injection 200IU

Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.

Intervention Type: DRUG

Leukocyte Interleukin, injection 400IU

Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.

Intervention Type: DRUG

Other Intervention Names

Multikine, Injection 200IU; Multikine, Injection 400IU

Eligibility Criteria

Inclusion Criteria

• ≥18 years of age
• Diagnosed with perianal condyloma by primary clinician
• HIV-infected, may be on or off of antiretroviral therapy
• any CD4 count will be considered appropriate for study
• Blood WBC > 2.0x103/mm3 and absolute neutrophils count > 500
• Blood hemoglobin > 10.0 g/dL
• Blood platelet count > 50x103/mm3
• Serum total bilirubin < 6.0 mg/dL (participants taking atazanavir-based ARV regimens may have elevated total bilirubin but are generally < 6)
• Blood aspartate aminotransferase (AST) < 100 U/L (<2 ULN)
• Blood alanine aminotransferase (ALT) < 130 U/L (<2 ULN)
• Serum creatinine < 1.5 mg/dL
• ECOG performance status < 3
• If a subject is of reproductive potential he/she and her/his sexual partner MUST be willing and able to utilize effective methods of contraception (e.g., birth control pill, barrier methods with spermicide - as applicable) for the duration of the study including the study follow-up period.

Exclusion Criteria

• Anal cancer (current or history of)
• Inability to attend study visits
• Participation in any other drug study
• History of asthma
• History of organ transplantation or requiring chronic administration of immune suppressive drugs in the last 6 months
• For women, neither pregnant nor lactating
• In the opinion of the PI, the subject may not be able to tolerate the study treatment regimen

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CEL-SCI Corporation

INDUSTRY

Sponsor Role: collaborator

United States Naval Medical Center, San Diego

FED

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John D Malone, MD

Role: PRINCIPAL_INVESTIGATOR

NMCSD

Locations

NMCSD

San Diego, California, United States

Countries

United States

Other Identifiers

NMCSD.2013.0080

Identifier Type: -

Identifier Source: org_study_id